{
    "id": 28857,
    "fullName": "SEPTIN3 - BRAF",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "SEPTIN3-BRAF results from the fusion of SEPTIN3 and BRAF, leads to increased phosphorylation of Mek and Erk, promotes invasion but not proliferation in cell culture (PMID: 30254212), and therefore, is predicted to lead to a gain of function. SEPTIN3-BRAF has been identified in melanoma (PMID: 30254212).",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 55964,
        "geneSymbol": "SEPTIN3",
        "terms": [
            "SEPTIN3",
            "bK250D10.3",
            "SEP3",
            "SEPT3"
        ]
    },
    "variant": "SEPTIN3 - BRAF",
    "createDate": "10/23/2018",
    "updateDate": "10/18/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 673,
                "geneSymbol": "BRAF",
                "terms": [
                    "BRAF",
                    "B-raf",
                    "B-RAF1",
                    "BRAF1",
                    "NS7",
                    "RAFB1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15107,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring SEPTIN3-BRAF showed no response when treated with Ulixertinib (BVD-523), as demonstrated by a lack of decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 30744,
                "profileName": "SEPTIN3 - BRAF"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15105,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring SEPTIN3-BRAF showed no response when treated with Zelboraf (vemurafenib), as demonstrated by a lack of decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 30744,
                "profileName": "SEPTIN3 - BRAF"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15106,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring SEPTIN3-BRAF showed no response when treated with Mekinist (trametinib), as demonstrated by a lack of decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 30744,
                "profileName": "SEPTIN3 - BRAF"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30744,
            "profileName": "SEPTIN3 - BRAF",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}